Integrated Biopharma Inc Quick Ratio (INBP) starting from the fourth quarter 2026 to fourth quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Integrated Biopharma Inc  (INBP)

Integrated Biopharma Inc's Quick Ratio

INBP's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the fourth quarter 2026, Quick Ratio fell to 0.77 above Integrated Biopharma Inc average.

Within Major Pharmaceutical Preparations industry 374 other companies have achieved higher Quick Ratio than Integrated Biopharma Inc in fourth quarter 2026. While Quick Ratio total ranking has improved so far during the Q4 2026 to 1953, from total ranking in the third quarter 2026 at 2639.

Explain Quick Ratio?
How much Cash & cash equivalents INBP´s has?
What are INBP´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

INBP Quick Ratio (Jun 30 2026)
Q4		 (Mar 31 2026)
Q3		 (Dec 31 2025)
Q2		 (Sep 30 2025)
Q1		 (Jun 30 2025)
Q4
Y / Y Current Liabilities Change 36.58 % 10.96 % -30.62 % -20.98 % -30.62 %
Y / Y Cash & cash equivalent Change 23.68 % 96.76 % 115.56 % 108.37 % 115.56 %
Quick Ratio MRQ 0.77 1.05 0.85 0.99 0.85
INBP's Total Ranking # 1953 # 2639 # 2280 # 2533 # 2948
Seq. Current Liabilities Change 4.98 % 30.11 % -10.83 % 12.15 % -14.72 %
Seq. Cash & cash equivalent Change -23.26 % 61.16 % -23.61 % 30.9 % 22.09 %



Quick Ratio fourth quarter 2026 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 375
Healthcare Sector # 680
Overall Market # 2209


Quick Ratio Statistics
High Average Low
1.05 0.2 0.01
(Mar 31 2026)   (Mar 31 2018)




Financial Statements
Integrated Biopharma Inc's Current Liabilities $ 6 Millions Visit INBP's Balance sheet
Integrated Biopharma Inc's Cash & cash equivalent $ 4 Millions Visit INBP's Balance sheet
Source of INBP's Sales Visit INBP's Sales by Geography


Cumulative Integrated Biopharma Inc's Quick Ratio

INBP's Quick Ratio for the trailling 12 Months

INBP Quick Ratio

 (Jun 30 2026)
12 Months		 (Mar 31 2026)
12 Months		 (Dec 31 2025)
12 Months		 (Sep 30 2025)
12 Months		 (Jun 30 2025)
12 Months
Y / Y Current Liabilities TTM Growth -4.86 % -19.22 % -27.67 % -15.92 % -11.26 %
Y / Y Cash & cash equivalent TTM Growth 77.16 % 107.17 % 95.2 % 78.27 % 38.35 %
Quick Ratio TTM 0.92 0.95 0.82 0.65 0.49
Total Ranking TTM # 1349 # 1729 # 1507 # 1769 # 2071
Seq. Current Liabilities TTM Growth 8.27 % 2.99 % -9.32 % -5.92 % -8.06 %
Seq. Cash & cash equivalent TTM Growth 4.81 % 19.2 % 14.92 % 23.38 % 22.57 %

Quick ratio ranking by company, industry and sector >> Back to INBP Financial Strength Comparisons >> Go to Compare INBP Quick Ratio to its Competitors

On the trailing twelve months basis Due to rise in Current Liabilities in the Q4 2026 to $5.80 millions, cumulative Quick Ratio decreased to 0.92 above the INBP average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 436 other companies have achieved higher Quick Ratio than Integrated Biopharma Inc. While Quick Ratio overall ranking has improved so far to 0, from total ranking during the twelve months ending third quarter 2026 at 3971.

Explain Quick Ratio?
How much Cash & cash equivalents INBP´s has?
What are INBP´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 437
Healthcare Sector # 896
Within the Market # 1953


trailing twelve months Quick Ratio Statistics
High Average Low
0.95 0.15 0.01
(Mar 31 2026)   (Sep 30 2021)




Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Major Pharmaceutical Preparations Industry Quick RatioJun 30 2026 MRQ Cash & cash equivalentJun 30 2026 MRQ Current Liabilities
Pacira Biosciences inc   2.06 $ 251.031  Millions$ 122.011  Millions
Genelux Corporation  2.05 $ 29.870  Millions$ 14.590  Millions
Opko Health Inc   2.01 $ 300.761  Millions$ 149.367  Millions
Corcept Therapeutics Inc  2.00 $ 308.197  Millions$ 153.802  Millions
Clene Inc   2.00 $ 9.700  Millions$ 4.852  Millions
Blue Water Vaccines Inc  2.00 $ 5.942  Millions$ 2.974  Millions
Vertex Pharmaceuticals Inc  1.99 $ 7,852.400  Millions$ 3,937.900  Millions
Metavia Inc   1.99 $ 12.636  Millions$ 6.346  Millions
Connect Biopharma Holdings Limited  1.93 $ 31.500  Millions$ 16.301  Millions
Amarin Corp Plcuk  1.92 $ 314.850  Millions$ 164.195  Millions
Mustang Bio inc   1.91 $ 15.150  Millions$ 7.918  Millions
Therapeuticsmd Inc   1.84 $ 9.189  Millions$ 5.003  Millions
Fortress Biotech Inc   1.81 $ 196.576  Millions$ 108.829  Millions
Maravai Lifesciences Holdings Inc   1.77 $ 70.091  Millions$ 39.519  Millions
Decoy Therapeutics Inc   1.77 $ 8.289  Millions$ 4.680  Millions
Hyperion Defi inc   1.75 $ 9.637  Millions$ 5.509  Millions
Verastem Inc   1.75 $ 136.400  Millions$ 78.130  Millions
Urogen Pharma Ltd   1.74 $ 108.000  Millions$ 61.915  Millions
Pyxis Oncology Inc   1.72 $ 47.141  Millions$ 27.474  Millions
Ernexa Therapeutics Inc   1.71 $ 5.028  Millions$ 2.932  Millions
Lantern Pharma Inc   1.70 $ 7.361  Millions$ 4.323  Millions
Nuvectis Pharma inc   1.67 $ 22.160  Millions$ 13.294  Millions
Quoin Pharmaceuticals Ltd   1.63 $ 10.800  Millions$ 6.613  Millions
Mallinckrodt Plc  1.63 $ 1,075.800  Millions$ 660.600  Millions
Macrogenics Inc   1.59 $ 173.305  Millions$ 108.815  Millions
Fibrobiologics Inc   1.59 $ 3.515  Millions$ 2.213  Millions
Sarepta Therapeutics Inc   1.57 $ 788.489  Millions$ 502.908  Millions
Revium Rx.  1.55 $ 1.506  Millions$ 0.971  Millions
Liquidia Corporation  1.50 $ 284.181  Millions$ 189.298  Millions
Greenwich Lifesciences Inc   1.50 $ 8.876  Millions$ 5.923  Millions

Date modified: 2026-09-26T08:07:57+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.